Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
16 févr. 2021 07h35 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
11 févr. 2021 22h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
11 févr. 2021 17h54 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
11 janv. 2021 07h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the...
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
12 nov. 2020 16h02 HE
|
Diffusion Pharmaceuticals Inc.
Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients Announces Next Steps in Development Program for Lead Product Candidate Ended Quarter with $21.9...
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
19 oct. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D....
Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary
24 sept. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the...
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
11 sept. 2020 08h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C....
Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial
10 sept. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the...
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
08 sept. 2020 16h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who...